EU court adviser backs Illumina's appeal against EU antitrust regulators' review of $7.1bn Grail deal.
EU court adviser backs Illumina in challenge against EU antitrust regulators' review of $7.1bn Grail deal. The European Union's Court of Justice was urged to support U.S. gene sequencing company Illumina's appeal against the EU antitrust regulators' review of its $7.1bn bid for cancer test maker Grail, according to an adviser to the court. The EU antitrust regulators have previously vetoed the deal and ordered Illumina to unwind the transaction.
March 21, 2024
6 Articles